{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-157364","form_type":"8-K","ticker":"STOK","cik":"0001623526","company_name":"Stoke Therapeutics, Inc.","filed_at":"2025-07-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.507033+00:00","generated_at":"2026-05-18T08:44:37.896930+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Stoke/Biogen present zorevunersen Phase 3 EMPEROR analysis showing cognition/behavior improvements at Week 68","bullets":["Analysis of patients on EMPEROR-like regimen (2x70mg loading + 2x45mg maintenance) showed cognition/behavior improvements at Week 68.","Results contrast with natural history (BUTTERFLY) where standard-of-care patients did not show improvements.","Five Vineland-3 sub-domains (Receptive/Expressive Communication, Interpersonal Relationships, Coping/Personal Skills) added as key secondary endpoints in Phase 3 EMPEROR.","Data complement prior Phase 1/2a and OLE results showing durable seizure reductions and improvements through two years.","Zorevunersen is a first-in-class potential disease-modifying RNA medicine for Dravet syndrome co-developed with Biogen."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-157364","json":"https://secwatch.observer/filing/0001193125-25-157364.json","markdown":"https://secwatch.observer/filing/0001193125-25-157364.md","text":"https://secwatch.observer/filing/0001193125-25-157364.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1623526/000119312525157364/0001193125-25-157364-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1623526/000119312525157364/d873782d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T08:44:37.896930+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}